Section of Clinical Neurology, Department of Neurological and Movement Sciences, University of Verona, Neurology Unit, Borgo Roma, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Ludovico Antonio Scuro 9, 37134 Verona, Italy.
Dis Markers. 2013;35(6):687-99. doi: 10.1155/2013/484959. Epub 2013 Nov 10.
Multiple sclerosis (MS) is a chronic disorder of the central nervous system (CNS) in which the complex interplay between inflammation and neurodegeneration determines varying degrees of neurological disability. For this reason, it is very difficult to express an accurate prognosis based on purely clinical information in the individual patient at an early disease stage. Magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) biomarkers are promising sources of prognostic information with a good potential of quantitative measure, sensitivity, and reliability. However, a comprehensive MS outcome prediction model combining multiple parameters is still lacking. Current relevant literature addressing the topic of clinical, MRI, and CSF markers as predictors of MS disability progression is reviewed here.
多发性硬化症（MS）是一种中枢神经系统（CNS）的慢性疾病，其中炎症和神经退行性变之间的复杂相互作用决定了不同程度的神经功能障碍。因此，很难根据个体患者在疾病早期的纯临床信息来准确预测预后。磁共振成像（MRI）和脑脊液（CSF）生物标志物是具有良好定量测量、敏感性和可靠性的预后信息的有希望的来源。然而，目前仍然缺乏综合多个参数的 MS 结局预测模型。本文综述了目前有关临床、MRI 和 CSF 标志物作为 MS 残疾进展预测因子的相关文献。
